



Transparency notification

Brussels (Belgium), 7 March 2017 – 20:00 (CET) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 2 March 2017, from BlackRock, Inc. (having its registered offices at 55 East 52nd Street, New York, NY, 10055, U.S.A.).

BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has decreased and has crossed downward the threshold of 3% of the voting rights on 28 February 2017.

On 28 February 2017, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 827 753 UCB shares with voting rights (versus 5 838 933 shares in its previous notification dated 28 February 2017), representing 2.996% of the total number of shares issued by the company (194 505 658) (versus 3.00% in the notification dated 28 February 2017).

2. Content of the notification

The transparency notification dated 2 March 2017 includes the following information:

- Reason for the notification: Acquisition or disposal of voting securities or voting rights
- **Notification by**: A parent undertaking or a controlling person.
- Persons subject to the notification requirement:





Name	Address (for legal entities)		
BlackRock, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.		
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands		
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore		
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.		
BlackRock Advisors, LLC	100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A.		
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada		
BlackRock Asset Management Deutschland AG	Max-Joseph-Straße 6, Munich, 80333, Germany		
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong		
BlackRock Financial Management, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.		
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.		
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.		
BlackRock International Limited	Exchange Place One, 1 Semple Street, Edinburgh, EH3 8BL, U.K.		
BlackRock Investment Management (Australia) Limited	Level 37, Chifley Tower, 2 Chifley Square, Sydney NSW 2000 Australia		
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.		
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.		
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan		

• Date on which the threshold is crossed: 28 February 2017.

• Threshold crossed (in %): 3%.

• **Denominator**: 194 505 658.

Notified details:





A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voti	ng rights	% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
BlackRock, Inc.	0	0		0,00%	
BlackRock (Netherlands) B.V.	18.125	18.125		0,01%	
BlackRock (Singapore) Limited	6.386	6.386		0,00%	
BlackRock Advisors (UK) Limited	839.243	873.961		0,45%	
BlackRock Advisors, LLC	62.122	62.122		0,03%	
BlackRock Asset Management Canada Limited	61.391	61.391		0,03%	
BlackRock Asset Management Deutschland AG	231.527	229.787		0,12%	
BlackRock Asset Management North Asia Limited	22.114	644		0,00%	
BlackRock Financial Management, Inc.	73.659	73.659		0,04%	
BlackRock Fund Advisors	1.805.379	1.807.552		0,93%	
BlackRock Institutional Trust Company, National Association	1.969.547	1.956.246		1,01%	
BlackRock International Limited	8.503	8.503		0,00%	
BlackRock Investment Management (Australia) Limited	41.852	41.852		0,02%	
BlackRock Investment Management (UK) Limited	229.398	264.970		0,14%	
BlackRock Investment Management, LLC	284.499	239.961		0,12%	
BlackRock Japan Co., Ltd.	185.188	182.594		0,09%	
Subtotal	5.838.933	5.827.753		3,00%	
TOTAL		5.827.753	0	3,00%	0,00%

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
BlackRock Advisors (UK) Limited	Securities Lent			88.634	0,05%	physical
BlackRock Fund Advisors	Securities Lent			1.118	0,00%	physical
BlackRock Institutional Trust Company, National Association	Securities Lent			9.606	0,00%	physical
BlackRock Institutional Trust Company, National Association	Contract for Difference			9.411	0,00%	cash
BlackRock International Limited	Contract for Difference			1.453	0,00%	cash
BlackRock Investment Management (UK) Limited	Contract for Difference			22.762	0,01%	cash
BlackRock Japan Co., Ltd.	Securities Lent			12.030	0,01%	physical
	TOTAL			145.014	0,07%	

TOTAL (A & B)		# of voting rights	% of voting rights	
	CALCULATE	5.972.767	3,07%	





• Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in the PDF which is attached to the notification.

Additional information:

The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going below 3%.

3. Further information

This press release and the detailed transparency notification is available on UCB SA/NV's website via the following <u>link</u>.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following <u>link</u>.

Investor Relations

Antje Witte, Investor Relations, UCB T +32 2 559 94 14, antje.witte@ucb.com Isabelle Ghellynck, Investor Relations, UCB T +32 2 559 95 88, isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (<u>www.ucb.com</u>) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 700 people in approximately 40 countries, the company generated revenue of €4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

